GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » vTv Therapeutics Inc (NAS:VTVT) » Definitions » Shiller PE Ratio

vTv Therapeutics (vTv Therapeutics) Shiller PE Ratio : (As of May. 01, 2024)


View and export this data going back to 2015. Start your Free Trial

What is vTv Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


vTv Therapeutics Shiller PE Ratio Historical Data

The historical data trend for vTv Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

vTv Therapeutics Shiller PE Ratio Chart

vTv Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

vTv Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of vTv Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, vTv Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Shiller PE Ratio falls into.



vTv Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

vTv Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, vTv Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.31/129.4194*129.4194
=-1.310

Current CPI (Dec. 2023) = 129.4194.

vTv Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -18.422 99.695 -23.915
201406 -9.026 100.560 -11.616
201409 -7.156 100.428 -9.222
201412 -9.405 99.070 -12.286
201503 -11.963 99.621 -15.541
201506 -53.310 100.684 -68.525
201509 -19.600 100.392 -25.267
201512 -14.000 99.792 -18.156
201603 -16.800 100.470 -21.641
201606 -18.800 101.688 -23.927
201609 -16.400 101.861 -20.837
201612 -16.800 101.863 -21.345
201703 -17.600 102.862 -22.144
201706 -16.400 103.349 -20.537
201709 -15.200 104.136 -18.891
201712 -17.600 104.011 -21.899
201803 -12.000 105.290 -14.750
201806 -12.400 106.317 -15.095
201809 -2.400 106.507 -2.916
201812 -4.000 105.998 -4.884
201903 -10.400 107.251 -12.550
201906 -4.000 108.070 -4.790
201909 -5.200 108.329 -6.212
201912 -5.200 108.420 -6.207
202003 -4.400 108.902 -5.229
202006 -2.800 108.767 -3.332
202009 -1.200 109.815 -1.414
202012 0.800 109.897 0.942
202103 -3.200 111.754 -3.706
202106 -0.400 114.631 -0.452
202109 -0.800 115.734 -0.895
202112 -4.400 117.630 -4.841
202203 -4.000 121.301 -4.268
202206 -1.600 125.017 -1.656
202209 -2.000 125.227 -2.067
202212 -2.400 125.222 -2.480
202303 -2.400 127.348 -2.439
202306 -2.800 128.729 -2.815
202309 -3.200 129.860 -3.189
202312 -1.310 129.419 -1.310

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


vTv Therapeutics  (NAS:VTVT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


vTv Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of vTv Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


vTv Therapeutics (vTv Therapeutics) Business Description

Traded in Other Exchanges
Address
3980 Premier Drive, Suite 310, High Point, NC, USA, 27265
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. The company lead program is TTP399, an orally administered, small molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes.
Executives
Steven L. Tuch officer: Chief Financial Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
John A Fry director C/O DELAWARE INVESTMENTS, 2005 MARKET ST. 34TH FL., PHILADELPHIA PA 19103
Jonathan Isaacsohn director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Paul J Sekhri director, officer: President and CEO C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Fahed Al-marzooqi director AL KHATEM TOWER, ABU DHABI GLOBAL MARKET, ABU DHABI C0 00000
Keith R. Harris director C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Hersh Kozlov director WOLF BLOCK SCHORR & SOLIS, 1940 RTE 70 E, CHERRY HILL NJ 08003
Howard L. Weiner director 4170 MENDENHALL OAKS PKWY, HIGH POINT NC 27265
Chandresh Harjivan director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Al-nahyan Tahnoon Bin Zayed S. 10 percent owner OFFICE 2458, FLOOR 24, AL-SILA TOWER, ABU DHABI C0 00000
G42 Investments Ai Holdings Rsc Ltd. director, 10 percent owner OFFICE 801, FLOOR 8, AL KHATEM TOWER, ABU DHABI C0 00000
Barry K. Brown officer: Chief Accounting Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Rich S. Nelson director, officer: Acting Chief Executive Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Ronald O Perelman 10 percent owner 35 EAST 62ND STREET, NEW YORK NY 10021
Deepa Prasad director, officer: President and CEO C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265

vTv Therapeutics (vTv Therapeutics) Headlines

From GuruFocus